The clinical characteristics and prognosis of COVID-19 patients with comorbidities: a retrospective analysis of the infection peak in Wuhan

Guifying Dong¹,²*, Zhe Du¹*, Jihong Zhu², Yang Guo¹, Weibo Gao², Wei Guo¹, Tianbing Wang¹, Baoguo Jiang¹

¹Trauma Center, Peking University People's Hospital, Key Laboratory of Trauma and Neural Regeneration (Peking University), Ministry of Education, Beijing, China; ²Emergency Department, Peking University People's Hospital, Beijing, China

Contributions: (I) Conception and design: B Jiang, T Wang; (II) Administrative support: None; (III) Provision of study materials or patients: B Jiang, T Wang; (IV) Collection and assembly of data: J Zhu, Y Guo, W Gao, W Guo; (V) Data analysis and interpretation: G Dong, Z Du; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Baoguo Jiang; Tianbing Wang. Trauma Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. Email: jiangbaoguo@vip.163.com; wangtianbing@pkuph.edu.cn.

Background: This study aims to determine the clinical characteristics and prognosis of COVID-19 patients with comorbidities and to identify survival factors.

Methods: A retrospective study was conducted in Wuhan, China, between February 8, 2020, and March 9, 2020. Based on underlying diseases, patients were assigned to either the comorbidity group or the non-comorbidity group. The clinical characteristics and outcomes of COVID-19 were analyzed and a Kaplan-Meier survival analysis was used to evaluate the prognosis predictive value of each comorbidity.

Results: During the study period, 278 COVID-19 patients were enrolled, 175 (62.95%) were assigned to the comorbidity group, and 103 (37.05%) to the non-comorbidity group. Of the patients in the comorbidity group, 34.86% were classified as critical. Further, patients in the comorbidity group had lower lymphocyte cell counts, and higher concentrations of D-dimer, high sensitivity C-reactive protein, interleukin 6, and serum ferritin as well as higher critical illness severity scores than patients in the non-comorbidity group (P<0.05). Patients in the comorbidity group also had higher mortality, acute respiratory distress syndrome, and ventilation treatment rates than patients in the non-comorbidity group (P<0.05). The length of hospital stay was longer in the comorbidity group than in the non-comorbidity group (P<0.05). The most common underlying diseases included hypertension (40.65%), diabetes mellitus (20.5%), and cardiovascular disease (19.42%). Patients with comorbidities were more likely to develop cardiovascular sequelae associated with COVID-19, shock, acute kidney injury, and multiple organ dysfunction syndrome (30.86% vs. 12.62%, P=0.001; 18.86% vs. 8.74%, P=0.023; 24.57% vs. 11.65%, P=0.009; 33.71% vs. 14.56%, P=0.000, respectively). In the Kaplan-Meier survival analysis, older patients (>65 years) (log-rank test: χ²=4.202, P=0.040) and patients with chronic obstructive pulmonary disease (COPD) (log-rank test: χ²=4.839, P=0.028) or diabetes mellitus (log-rank test: χ²=4.377, P=0.036) had shorter survival than those without comorbidities.

Conclusions: Patients with comorbidities were more severely affected and had a higher mortality rate. Age, COPD and diabetes mellitus were the main factors affecting the survival of patients.

Keywords: COVID-19; hospital mortality; ARDS; comorbidity

doi: 10.21037/atm-20-4052

View this article at: http://dx.doi.org/10.21037/atm-20-4052
Introduction

In December 2019, a number of patients presented with pneumonia caused by an unknown aetiology emerged in Wuhan, provincial capital of Hubei province, China. This new coronavirus has been termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it has caused a considerable number of infections and deaths in and beyond China, and have turned into a worldwide pandemic (1). Up until March 30, 2020, there were more than 81,470 identified cases of COVID-19 in China, with 738,679 identified cases and 35,012 deaths worldwide (2).

Based on previous studies on the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) conducted in 2003 and 2012, respectively, researchers investigated COVID-19 patients with specific underlying diseases (3-7). Recent studies have reported that patients with comorbidities have a higher number of complications than those without underlying diseases and comorbidities; these are risk factors for adverse outcomes (8-12). Therefore, the aim of this study was to retrospectively analyze and compare the clinical characteristics and prognosis between the comorbidity group and the non-comorbidity group, in order to assess risk factors affecting survival from the phrase of infection peak in Wuhan. We present the following article in accordance with the STROBE reporting checklist (available at http://dx.doi.org/10.21037/atm-20-4052).

Methods

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Ethics Committee of the Peking University People’s Hospital approved this study (2020PHB080-01). Written informed consent was waived due to the rapid emergence and progression of COVID-19.

Participants and parameters

This retrospective study was conducted at a single academic tertiary care hospital. According to the guideline for the Diagnosis and Treatment of COVID-19 Infections (13), a patient suffering from COVID-19 was defined as someone with a positive 2019-nCoV nucleic acid test using real-time RT-PCR conducted with a pharyngeal swab. Between February 8, 2020, and March 9, 2020, patients who were diagnosed with a COVID-19 infection were admitted to the Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, managed by the Peking University People’s Hospital medical team.

Data were collected by trained doctors and documented using standardized web-based case report forms (eCRF). Demographic data, comorbidities, complications, dates of admission, clinical classifications (ordinary, severe and critical) (13), and the date of discharge from the hospital were documented. The critical illness severity score was calculated using the Sequential Organ Failure Assessment (SOFA) (14), with the SpO₂/FiO₂ ratio reported instead of the PaO₂/FiO₂ ratio (15), along with the specific pneumonia severity score, CURB-65 (16). The complete blood count was measured using the Sysmex XN-9000 automatic hematology analyzer (Sysmex, Japan). The coagulation parameter tests, including the D-dimer test, were performed using the Stago STA-R automatic blood coagulation analyzer (Stago, France). Serum ferritin was measured using the Roche Cobas 8000 automatic biochemical analyzer (Roche, Switzerland). Interleukin 6 (IL-6) was detected using the Roche Cobas e602 electrochemical luminescence analyzer (Roche, Germany). The laboratory tests were repeated at intervals of 1, 3 and 5 days for critical, severe and ordinary patients. The highest score and worst laboratory values were selected for analysis.

Based on whether patients had the following underlying diseases: hypertension, diabetes mellitus, cardiovascular diseases, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), chronic liver disease, and malignant tumor, they were assigned to either of the following two groups: the comorbidity or the non-comorbidity group. Comorbidities listed here are the medical diagnoses included in patient’s medical history using the ICD-10 coding.

Inclusion and exclusion criteria

All patients aged 18 years or older diagnosed with COVID-19 using RT-PCR who visibly manifested symptoms of pneumonia on computed tomography (CT) images were eligible for the study. To meet the inclusion criteria, the patient’s CT imaging had to reveal multiple small patches of shadows and interstitial changes, especially in the lung periphery, or multiple ground-glass shadows, infiltration shadows, and lung consolidation.

Patients who were hospitalized for less than 24 hours, were in a state of arrest at arrival, or had incomplete clinical data were excluded from the study. A flow chart of the
exclusion criteria used in our study is shown in Figure 1.

**Patient enrolment**

During the study period, a total of 295 patients with COVID-19 visited our wards. All the patients had pneumonia with abnormal chest CT imaging findings. Of these patients, 17 were excluded. The reasons for exclusion included hospitalization for less than 24 h (n=2), state of arrest at arrival (n=1), and incomplete clinical data (n=14). As a result, 278 patients were included in the final analysis (Figure 1). All patients received standardized treatment according to the Guideline for the Diagnosis and Treatment of COVID-19 Infections (13). Patients who were still in hospital on March 9, 2020 were deemed to be survivors. The post-discharge follow-up time was 14 days. None of the patients were readmitted during this period with a COVID-19 infection.

**Clinical outcomes**

In this study, the primary outcome was mortality within 28 days. ARDS (17), ventilation treatment rates and the length of stay (LOS) at the hospital viewed as the secondary outcomes.

**Statistical analysis**

SPSS 25.0 statistical software and GraphPad Prism mapping software were used to conduct data analysis. Non-normally distributed continuous variables were presented as median (Q25, Q75) and compared using the Mann-Whitney U test. Categorical data were reported as proportions and compared using the Chi-squared test. The cumulative survival rate within 28 days was analyzed using a Kaplan-Meier survival curve.

**Results**

**General information**

A total of 175 (62.95%; male to female ratio, 94:81) patients were assigned to the comorbidity group. Of those, 55 (31.43%) were classified as ‘ordinary’, 59 (33.71%) as ‘severe’, and 61 (34.86%) as ‘critical’. Of the patients in the non-comorbidity group (male to female ratio, 52:51), 51 (49.51%) were classified as ‘ordinary’, 37 (35.92%) as ‘severe’, and 15 (14.56%) as ‘critical’. The proportion of cases classified as ‘critical’ was higher in the comorbidity group than in the non-comorbidity group (P=0.000). As shown in Table 1, the median age was significantly higher in the comorbidity group (67 years; range, 58–73) than in the non-comorbidity group (56 [42–64] years, P=0.000), as were the SOFA scores (median: 2 [1–6] vs. 1 [0–3]; P=0.001) and CURB-65 score (median: 1 [1–3] vs. 0 [0–1], P=0.000).

**Laboratory testing**

Laboratory testing revealed that patients in the comorbidity
group had significantly lower lymphocyte count than patients in the non-comorbidity group [median: 0.85 (0.44–1.56) vs. 1.6 (0.84–2.12), P=0.000]. Furthermore, patients in the comorbidity group had higher concentrations of D-dimer, high sensitivity C-reactive protein (hsCRP), IL-6, and serum ferritin than patients in non-comorbidity group [median: 1.80 (0.52–9.98) vs. 0.48 (0.22–1.47), P=0.000; 39.20 (3.10–152.90) vs. 4.6 (1.1–47.75), P=0.000; 19.70 (4.05–93.55) vs. 3.70 (1.5–23.15), P=0.000; 622.80 (318.45–1,574.00) vs. 477.00 (159.10–883.05), P=0.000], as shown in Figure 2.

**Patient outcomes**

As shown in Table 2, the in-hospital mortality, ARDS, and ventilation treatment rates of patients in the comorbidity group were higher than those for the patients in the non-comorbidity group (28.57% vs. 12.62%, P=0.002; 60.57% vs. 54.34%, P=0.000).
vs. 46.60%, P=0.024; 31.43% vs. 12.62%, P=0.000; respectively). In addition, LOS was longer among patients in comorbidity group than those in non-comorbidity group [median: 16 [9–23] vs. 13 [6–19]; P=0.016].

Complications during the hospital stay

An analysis of the comorbidities suggested that the prevalence of hypertension, diabetes mellitus, cardiovascular diseases, COPD, and CKD among our patients was 40.65%, 20.50%, 19.42%, 8.99%, and 5.76%, respectively. Furthermore, 73 (26.26%) patients had multimorbidity. Except for liver enzyme abnormalities, in terms of complication rates, COPD was the highest, followed by cardiovascular diseases, diabetes mellitus, and hypertension. Additional characteristics are presented in Table 3.

In addition to ARDS, patients with comorbidities were more likely to develop cardiovascular sequelae associated with COVID-19 (CSAC) (4), shock, acute kidney injury (AKI), and multiple organ dysfunction syndrome (MODS) (30.86% vs. 12.62%, P=0.001; 18.86% vs. 8.74%, P=0.023; 24.57% vs. 11.65%, P=0.009; 33.71% vs. 14.56%, P=0.000; respectively) (Table 4).

Survival analysis

The Kaplan-Meier survival analysis using a log-rank test suggested that older patients (≥65 years) (log-rank test: \( \chi^2 = 4.202 \), P=0.040), patients with COPD (log-rank test: \( \chi^2 = 4.839 \), P=0.028), or diabetes mellitus (log-rank test: \( \chi^2 = 4.377 \), P=0.036) were found to have significantly shorter survival periods, as shown in Figure 3. Hypertension, cardiovascular diseases, malignancy tumor, chronic liver disease, and CKD did not show statistically significant differences.

Table 2 Clinical outcomes of the comorbidity and non-comorbidity groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Comorbidity group (n=175)</th>
<th>Non-comorbidity group (n=103)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital mortality, n (%)</td>
<td>50 (28.57)</td>
<td>13 (12.62)</td>
<td>0.002</td>
</tr>
<tr>
<td>ARDS, n (%)</td>
<td>106 (60.57)</td>
<td>48 (46.60)</td>
<td>0.024</td>
</tr>
<tr>
<td>LOS (days), median [Q25–Q75]</td>
<td>16 [9–23]</td>
<td>13 [6–19]</td>
<td>0.016</td>
</tr>
<tr>
<td>Ventilation treatment, n (%)</td>
<td>55 (31.43)</td>
<td>13 (12.62)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Table 3 Cause-specific complications rates of patients (n=175)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hypertension</th>
<th>Diabetes mellitus</th>
<th>Cardiovascular disease</th>
<th>chronic obstructive pulmonary disease</th>
<th>chronic kidney disease</th>
<th>Malignancy tumor</th>
<th>Chronic liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence, n (%)</td>
<td>113 (40.65)</td>
<td>57 (20.50)</td>
<td>53 (19.06)</td>
<td>25 (8.99)</td>
<td>16 (5.76)</td>
<td>10 (3.60)</td>
<td>7 (2.52)</td>
</tr>
<tr>
<td>Mortality, n (%)</td>
<td>27 (23.89)</td>
<td>18 (31.58)</td>
<td>19 (35.85)</td>
<td>11 (44.00)</td>
<td>1 (6.25)</td>
<td>4 (40.00)</td>
<td>3 (42.86)</td>
</tr>
<tr>
<td>ARDS, n (%)</td>
<td>66 (58.41)</td>
<td>34 (59.65)</td>
<td>38 (71.70)</td>
<td>18 (72.00)</td>
<td>5 (31.25)</td>
<td>5 (50.00)</td>
<td>4 (57.14)</td>
</tr>
<tr>
<td>CSAC, n (%)</td>
<td>32 (28.32)</td>
<td>17 (29.82)</td>
<td>22 (41.51)</td>
<td>12 (48.00)</td>
<td>5 (31.25)</td>
<td>4 (40.00)</td>
<td>2 (28.57)</td>
</tr>
<tr>
<td>Shock, n (%)</td>
<td>19 (16.81)</td>
<td>10 (17.54)</td>
<td>12 (22.64)</td>
<td>10 (40.00)</td>
<td>–</td>
<td>3 (30.00)</td>
<td>3 (42.86)</td>
</tr>
<tr>
<td>AKI, n (%)</td>
<td>25 (22.12)</td>
<td>14 (24.56)</td>
<td>17 (32.08)</td>
<td>9 (36.00)</td>
<td>–</td>
<td>4 (40.00)</td>
<td>2 (28.57)</td>
</tr>
<tr>
<td>Coagulation disorder, n (%)</td>
<td>7 (6.19)</td>
<td>5 (8.77)</td>
<td>5 (9.43)</td>
<td>3 (12.00)</td>
<td>–</td>
<td>3 (30.00)</td>
<td>2 (28.57)</td>
</tr>
<tr>
<td>Liver dysfunction, n (%)</td>
<td>28 (24.78)</td>
<td>10 (17.54)</td>
<td>15 (28.30)</td>
<td>7 (28.00)</td>
<td>2 (12.50)</td>
<td>3 (30.00)</td>
<td>1 (14.29)</td>
</tr>
<tr>
<td>MODS, n (%)</td>
<td>40 (35.4)</td>
<td>22 (38.60)</td>
<td>28 (52.83)</td>
<td>20 (80.00)</td>
<td>7 (43.75)</td>
<td>5 (50.00)</td>
<td>3 (42.86)</td>
</tr>
</tbody>
</table>

ARDS, acute respiratory distress syndrome; CSAC, cardiovascular sequelae associated with COVID-19; AKI, acute kidney disease; MODS, multiple organ dysfunction syndrome.

© Annals of Translational Medicine. All rights reserved.

Ann Transl Med 2021;9(4):280 | http://dx.doi.org/10.21037/atm-20-4052
Discussion

Key findings

Among our study participants, patients with comorbidities were older, had more critical illnesses, and tended to experience complications with various organ functions, such as ARDS and CSAC, which increased the mortality and the LOS. Among several comorbidities that were considered in this study, diabetes mellitus and COPD significantly shortened the cumulative survival time, suggesting a poor prognosis.

Comparisons with previous studies

As observed in previous studies (18,19), nearly 32–72.8% of the COVID-19 patients had underlying diseases. Previous evidence suggests that older patients with comorbidities are the most susceptible to SARS-CoV-2 infections, consequently, they have poor clinical outcomes (7,10). While studies have suggested that comorbidities affect the function of the immune system, which in turn directly impacts the response to COVID-19 as well as the change progression and prognosis of COVID-19 (20,21). It is worth noting that in our study, the comorbidity group accounted for 62.95% of the patients, and of those, 61 (34.86%) patients were classified as ‘critical’ and had higher SOFA and CURB-65 scores. Furthermore, in our study, 50 (41.67%) patients in the comorbidity group died at 28 days, which is a lower ratio than that reported in previous studies (8,19). The patients were classified and managed according to whether they had concomitant diseases or not (22), which reduced the mortality to a certain extent (P=0.002). So it is necessary for medical staff to strengthen the evaluation and management of patients with comorbidities.

In our cohort, lymphocytopenia as well as the increase in the concentrations of hsCRP, D-dimer, IL-6, and serum ferritin were observed in patients with comorbidities, which is congruent with the findings of previous studies (8,19,23). These features were similar to the pathogenesis of the “cytokine storm syndrome” in patients with hemophagocytic lymphohistiocytosis or the macrophage

Table 4 Clinical outcomes of patients with and without underlying diseases (n=278)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Comorbidity group (n=175)</th>
<th>Non-comorbidity group (n=103)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSAC, n (%)</td>
<td>54 (30.86)</td>
<td>13 (12.62)</td>
<td>0.001</td>
</tr>
<tr>
<td>Shock, n (%)</td>
<td>33 (18.86)</td>
<td>9 (8.74)</td>
<td>0.023</td>
</tr>
<tr>
<td>AKI, n (%)</td>
<td>43 (24.57)</td>
<td>12 (11.65)</td>
<td>0.009</td>
</tr>
<tr>
<td>Coagulation disorder, n (%)</td>
<td>19 (10.86)</td>
<td>10 (9.71)</td>
<td>0.762</td>
</tr>
<tr>
<td>Liver enzyme abnormality, n (%)</td>
<td>46 (26.29)</td>
<td>33 (32.04)</td>
<td>0.304</td>
</tr>
<tr>
<td>MODS, n (%)</td>
<td>59 (33.71)</td>
<td>15 (14.56)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

CSAC, cardiovascular sequelae associated with COVID-19; AKI, acute kidney disease; MODS, multiple organ dysfunction syndrome.

Figure 3 The Kaplan-Meier survival curve of the patients.
activation syndrome (24). In other words, the inflammatory response of patients with comorbidities was more severe.

Furthermore, among our participants, hypertension was the most common underlying disease, followed by diabetes mellitus, and cardiovascular diseases, which was consistent with findings from previous reports (9,19,20,25). Nearly 38.86% (68/175) of the patients had comorbidities related to organ dysfunction, the most common of which was ARDS, followed by CSAC. Existing studies also indicated that COVID-19 can be complicated by various organ injuries, especially among patients who did not survive (18,26,27).

The most recent studies have found that older age, higher SOFA scores, D-dimer concentrations greater than 1 μg/mL at admission, and comorbidities were associated with a poor prognosis (8,9,18,28). In our study, age, diabetes mellitus, and COPD showed a significant association with poor clinical outcomes in the studied cohort. Studies of COVID-19 with single comorbidity, have found to date, that hypertension, CKD, and cardiovascular diseases are associated with poor prognosis (5,7,10,11). However, in our study, other “traditional” risk factors among chronic comorbidities did not seem to be associated with poor prognosis. The reason for the differences between the studies may be due to the fact that the dissimilarity between countries and regions, the types and numbers of comorbidities included in the analysis, as well as the statistical methods were different (5,10,29,30).

Limitations

First, due to the different classification of illness severity in our patients, the results of the blood gas analysis for all patients could not be obtained; hence, we used the SpO$_2$/FiO$_2$ ratio instead of the PaO$_2$/FiO$_2$ ratio to evaluate the oxygenation status of our patients. However, Chen’s study showed that patients with ARDS diagnosed using the SpO$_2$/FiO$_2$ ratio have very similar clinical characteristics and outcomes compared to patients diagnosed using the PaO$_2$/FiO$_2$ ratio (14). Second, since this study was conducted at a single center in China, the generalizability of our results, globally, especially with respect to race and ethnicity during the pandemic, is limited and should to be verified by studies with larger sample sizes. Nonetheless, the association between ethnicity and COVID-19 mortality after adjustment for comorbidities is not reassuring (31). Lastly, due to the retrospective study design, data integrity cannot be guaranteed, which can affect the research results.

Conclusions

Patients with comorbidities were more severely affected and had a higher mortality rate. Age, COPD and diabetes mellitus were the main factors affecting the survival of patients. Strengthening the management of the comorbidities and the risk factors can be effective in reducing the severity of COVID-19 as well as the future incidence of severe cases and the death rate of COVID-19.

Acknowledgments

The authors thank Liting Zhao, Lisha Tian and Lin Qiao from the trauma center of Peking University People’s Hospital for their involvement in the collection of the data. Concurrently, we would also like to thank our colleagues from Peking University First Hospital and Peking University Third Hospital for their contributions towards the management of the patients.

Funding: This study was supported by the Michigan Medicine-Peking University Health Science Center Joint Institute for Translational and Clinical Research (BMU20160527) and Peking University Clinical Scientist Program, the Fundamental Research Funds for the Central Universities (BMU2019LCKXJ005).

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-4052

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-4052

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-4052). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work and for ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The Ethics Committee of the Peking University People’s Hospital approved this study (2020PHB080-01). Written informed consent was waived.
due to the rapid emergence and progression of COVID-19.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


